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Objective: The diagnostic boundaries of sleep disorders are under considerable debate. The main sleep
disorders are partly heritable; therefore, deﬁning heritable pathophysiologic mechanisms could delin-
eate diagnoses and suggest treatment. We collected clinical data and DNA from consenting patients
scheduled to undergo clinical polysomnograms, to expand our understanding of the polymorphisms as-
sociated with the phenotypes of particular sleep disorders.
Methods: Patients at least 21 years of age were recruited to contribute research questionnaires, and to
provide access to their medical records, saliva for deoxyribonucleic acid (DNA), and polysomnographic
data. From these complex data, 38 partly overlapping phenotypes were derived indicating complaints,
subjective and objective sleep timing, and polysomnographic disturbances. A custom chip was used to
genotype 768 single-nucleotide polymorphisms (SNPs). Additional assays derived ancestry-informative
markers (eg, 751 participants of European ancestry). Linear regressions controlling for age, gender, and
ancestry were used to assess the associations of each phenotype with each of the SNPs, highlighting those
with Bonferroni-corrected signiﬁcance.
Results: In peroxisome proliferator-activated receptor gamma, coactivator 1 beta (PPARGC1B), rs6888451
was associated with several markers of obstructive sleep apnea. In aryl hydrocarbon receptor nuclear
translocator-like (ARNTL), rs10766071 was associated with decreased polysomnographic sleep dura-
tion. The association of rs3923809 in BTBD9 with periodic limb movements in sleep was conﬁrmed. SNPs
in casein kinase 1 delta (CSNK1D rs11552085), cryptochrome 1 (CRY1 rs4964515), and retinoic acid receptor-
related orphan receptor A (RORA rs11071547) were less persuasively associated with sleep latency and
time of falling asleep.
Conclusions: SNPs associated with several sleep phenotypes were suggested, but due to risks of false dis-
covery, independent replications are needed before the importance of these associations can be assessed,
followed by investigation of molecular mechanisms.
© 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-SA
license (http://creativecommons.org/licenses/by-nc-sa/3.0/).
1. Introduction
Sleep disorders are an expanding arena of medical research. For
decades, insomnia has been the primary focus and it may remain
the most frequently treated sleep disorder with the greatest total
medical cost. Insomnia is strongly associated with depression and
other emotional disorders, which seemingly contribute to each other.
However, expanding data indicate that sleep-disordered breath-
ing may be more common than insomnia [1,2]. Further, sleep-
disordered breathingmight be associated with higher morbidity and
mortality. With or without comorbid insomnia complaints, re-
ported sleep durations either several hours longer or shorter than
the population median are associated with elevated mortality risks
and numerous morbidities [3–5]. Contrary to popular belief, re-
ported sleep durations longer than the epidemiologic optimum
appear more common than short sleep [4]. Reported long sleep may
be the best-documented mortality risk factor among the sleep dis-
orders, and long sleep is associated with more serious morbidities
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[3,6]. Willis–Ekbom disease (restless legs syndrome or RLS) might
have a prevalence of 3–15% [7,8], but its associations with morbid-
ity and mortality have not yet been fully clariﬁed. Among the
circadian rhythm sleep disorders, delayed sleep-phase disorders
(DSPDs) are an increasing concern among adolescents and young
adults [9,10]. Delayed sleep phase is associated with broad health
impairments and possibly, when the disturbance is persistent, a DSPD
leads to excess mortality [11]. Narcolepsy was one of the ﬁrst sleep
disorders characterized. Although narcolepsy can be quite dis-
abling, the prevalence appears to be less than one per thousand [12].
The diagnostic deﬁnitions of these sleep disorders have been
somewhat controversial and have often varied among successive
presentations of standard criteria, suggesting uncertainties in the
diagnostic formulations. The population prevalence of these sleep
disorders is poorly deﬁned due to frequent changes in the diag-
nostic formulations. Validations of the most recent criteria by
predicted prognoses and responses to treatment are scanty. Various
sleep disorders are frequently comorbid and may have common
symptoms such as trouble falling asleep, excess arousals during sleep,
daytime sleepiness, and fatigue. It may be diﬃcult for the clini-
cian to isolate the various factors causing the symptoms in order
to focus on the most useful targets for intervention.
All of the sleep disorders mentioned above are somewhat or
strongly heritable, with genetic components of causation [12–16].
Clariﬁcation of the genetic predispositions might lead to better un-
derstanding of pathophysiologic mechanisms, more useful diagnostic
formulations, and ultimately better approaches to treatment. Up to
now, with the exception of polymorphisms associated with narco-
lepsy [12,17,18], the identiﬁed polymorphisms associated with sleep
disorders explain only small parts of their heritability and prevalence.
To expand understanding of genetic variants associatedwith sleep
disorders, we systematically collected research questionnaires and
DNA from patients scheduled to undergo clinical polysomnograms
at the Scripps Clinic Viterbi Family Sleep Center.
2. Methods
2.1. Recruitment and procedure
From June 2006 toMay 2010, whenever practical, patients sched-
uled for polysomnography (PSG)were invited to participate in genetic
research. Patients 21 years and older were included, provided they
competently signed informed written consent, under supervision
of the Scripps Human Research Participant Protection Program and
Institutional Review Board and in compliance with the Helsinki Dec-
laration. Patients were not paid for research participation. Saliva was
collected in Oragene saliva kits (DNA Genotek Inc., Kanata, Ontario,
Canada). Then DNA was puriﬁed according to the Oragene proto-
col and the samples were frozen.
An extensive symptom questionnaire was completed by pa-
tients for clinical purposes with the help of family or staff as needed,
and the same questionnaire was used for the research. The ques-
tionnaire included queries about sleep habits and schedules; sleep
onsets and awakening times on weekdays and weekends; napping;
and numerous items concerning symptoms of disturbed sleep,
daytime sleepiness, narcoleptic symptoms, restless legs, and sleep-
disordered breathing. Limited demographic items were included.
The questionnaire included four key questions about restless legs
used to recognize Willis–Ekbom disease [19], the Epworth Sleep-
iness Scale (ESS) [20], the Basic Language Morningness scale (BALM,
a circadian morningness–eveningness trait measure) [21], and the
Quick Inventory of Depressive Symptomatology-Self Report (QIDS-
SR) scale evaluating current depressive symptoms [22]. Both
International Classiﬁcation of Sleep Disorders (ICSD) [23] research
diagnoses recorded by the sleep specialist administering the intake
questionnaire and the International Classiﬁcation of Diseases (ICD)-9
diagnoses recorded over recent months in our electronic medical
information system were retrieved and coded.
2.2. Polysomnography
After the polysomnogram was recorded and reviewed, the
research database was coded with statistics such as the
polysomnographic total sleep time, sleep latency, rapid eye move-
ment (REM) latency, sleep eﬃciency, REM and slow-wave sleep
percentages, total number and number per hour of obstructive and
central apneas, apnea–hypopnea index (AHI), pulse-oximetry mea-
surement of the 3% oxygen desaturation index (ODI3), percent of
sleep time when oxygen saturation was <80%, and the periodic leg
movement index. Logarithmic transforms were also tested for highly
skewed parameters. Polysomnography scoring used contempo-
rary American Academy of Sleep Medicine (AASM) criteria, which
underwent several modiﬁcations during the study. When a patient
was observed to display substantial sleep-disordered breathing in
the ﬁrst part of the polysomnogram, often a split-night procedure
was implemented to save the clinical expense of extra recording
nights. On 416 split nights, the ﬁrst portion of the night was devoted
to uninterrupted recording to assess the degree of sleep-disordered
breathing. Then the remainder of the night was devoted to
sometimes-disturbing technician interventions to initiate contin-
uous positive airway pressure (CPAP) treatment; adjust masks; titrate
pressures to ﬁnd optimal responses; change CPAP to bilevel, auto-
adjusting, and paced ventilatory support protocols; provide
supplemental oxygen, etc. For analyses of polysomnographic total
sleep time (tstpsg), only recordings with uninterrupted time in bed
(tib) > 300 min were used (N = 517), which included 99.6% of the
full-night recordings but excluded 99% of the split-night record-
ings wherein sleep was artiﬁcially curtailed. If the patient wore CPAP
or used supplemental oxygen during an entire undisturbed record-
ing (without technician interventions and titrations), those data were
also used. Patients received their usual medications on recording
nights.
Strengths and limitations of the polysomnographic data collec-
tion strategy should be noted. The patient sample was recruited from
a busy academic sleep practice, ﬁrst established in 1983. The
polysomnographic recordings followed approved AASM proce-
dures in this accredited sleep center, overseen by clinicians most
of whom were diplomats of the American Board of Sleep Medi-
cine. As such, the clinical sample was generally representative of
patients referred for sleep disorders specialist consultation,
except that there was a bias against participants for whom
polysomnography might not be indicated (eg, a bias against
patients referred primarily for insomnia, restless legs complaints,
or circadian rhythm phase disorders). Indeed, almost all patients
for whom polysomnography was ordered carried a before-
polysomnography diagnosis of some form of sleep apnea (whether
the clinician thought the pretest probability high or low), perhaps
inﬂuenced by clinician knowledge that other diagnoses were less
likely to earn insurance preapproval for laboratory polysomnographic
testing. As our sleep center is located at a department of chest med-
icine and staffed mainly by pulmonologists (not atypical), when the
clinical focus was on sleep apnea, comorbid conditions such as pe-
riodic limb movement disorders, insomnia, or circadian rhythm
disorders might not be explored with equal interest, and when
comorbid with sleep apnea, these diagnoses might not be coded.
The severe limitation of these procedures for research was the vari-
ability of polysomnographic recording conditions, especially
recording duration, for measurement of polysomnographic param-
eters such as total sleep time or REM sleep percentage. The advantage
of the strategy was that assessments of sleep-disordered breath-
ing are often thought to have adequate clinical reliability on
split nights [24,25], whereas the cost of performing a research
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recording for each participant would have added $1,000,000–
$2,000,000 to research expenses and would have limited the sample
as well. It is doubtful that as high a percentage of our patients would
have agreed to recordings primarily for research purposes, and some
already using CPAP would not have agreed to recordings without
CPAP.
Even when performed for a research purpose, recordings using
standard methods to monitor sleep-disordered breathing and pe-
riodic limb movements are known to produce discomforts and
substantial sleep disturbances not usually experienced by pa-
tients in their home environments, although the homemay produce
disturbances as well. Single-night recordings do not provide highly
repeatable measurements of total sleep time, sleep apnea, and pe-
riodic limbmovements, whether performed on a clinical or research
basis [26–28].
2.3. Phenotype assembly
From an enormous quantity and complexity of questionnaire, di-
agnostic, and polysomnographic data, the clinical data were
prospectively distilled to 38 phenotype measures, focusing on com-
plaints of insomnia and excessive daytime sleep, symptoms of
depression, duration and time of day spent in bed, total subjective
and polysomnographic sleep time, symptoms of restless legs [29],
polysomnographic periodic leg movements, and several interre-
lated parameters of sleep apnea. Deﬁnitions of the phenotype
variables are presented in the “Phenotype Deﬁnitions” worksheet
of Supplement S1, which explains how each phenotype was coded
and lists the numerical distributions of each phenotype. The text
of the research questionnaire is attached as Supplement S2.
2.4. Genotyping
DNA was assayed primarily with a custom Illumina Golden Gate
assay for 768 single nucleotide polymorphisms, designed as part
of a multi-center collaboration [30]. Most targeted polymor-
phisms were selected for relevance to circadian rhythm regulation,
but a smaller number were selected based on previous reports of
association with sleep disorders [31]. Previous aspects of our re-
search including detailed assay methods for this genotyping have
been presented in prior reports, especially in two reports of asso-
ciations of these same genotypes with circadian rhythm sleep
disorders (delayed sleep phase and non-24-h sleep–wake cycles)
and with mood symptoms [32–37]. A few single-nucleotide poly-
morphisms (SNPs) of special interest were assayed using additional
Sequenom, SNPlex, and Taqman assays, as well as some of 27
ancestry-informative markers (AIMS) used to develop multidimen-
sional scale (MDS) dimensions within participants of European
ancestry [38]. The MDS components were used as regression
covariates to control for ancestry stratiﬁcation within the Europe-
an ancestry portion of the sample (751 of European ancestry) and
were usually useful in reducing genomic inﬂation of the regres-
sion results. Additional MDS components for all ancestries were
derived to examine participants of all ancestries together or to
examine those 86 of non-European ancestry separately. The latter
included those of Asian, African, Native American, and mixed
ancestries.
2.5. Statistical analyses
The PLINK whole genome analysis tool set [39] was used to
compute linear or logistic regression analyses of the association
between each phenotype and the available SNPs. The regression
models were selected with a goal of maximizing validity. A primary
goal was curtailing genomic inﬂation as much as possible, by using
age, sex, and multidimensional scale factors as covariates to control
stratiﬁcation and by excluding violations of Hardy–Weinberg equi-
librium or low minor allele frequencies. In some cases, eliminating
one or more covariates reduced the genomic inﬂation. It appeared
advisable at times to allow minor alleles with <1% frequency, two
of which relatively rare variants appeared of considerable interest
as reported below. In most cases, we only tested additive models
a priori to avoid further inﬂation of the multiple-testing burden, but
prior data on heritability suggested dominant models for the BALM
and DSPS phenotypes [40,41]. Regressions for up to 626 SNPs were
computed, requiring Bonferroni correction for multiple compari-
sons to obtain the family-wise error rates, in order to minimize false
positives. We emphasize those associations with a phenotype which
met a Bonferroni-corrected criterion of P < 0.05, but we also ﬂag
nominally signiﬁcant P < 0.05 values, which should not be consid-
ered signiﬁcant by the Bonferroni criteria. To obtain an overall
perspective on the statistical outcomes considering the linkage of
many of the SNPs and the correlations among many of the depen-
dent phenotypes, we computed the q-values (false discovery rates)
of all of the P values harvested from the 38 regressions combined,
using the method and R statistical program with the default pa-
rameters of Storey and Tibshirani [42].
Because most of the participants had European ancestries, we
focused on those participants to minimize stratiﬁcation, as we gen-
erally did not ﬁnd the MDS factors suﬃcient to control genomic
inﬂation in samples of mixed ancestry, nor did adding non-Europeans
to the European sample yield more powerful outcomes. The 86
samples of the non-European ancestry group were too few in them-
selves to expect adequate statistical power after Bonferroni correction.
3. Results
There were 13 Bonferroni-signiﬁcant associations of SNPS with
11 phenotypes, which are presented in Table 1. This included three
SNPs of the fragile X mental retardation 1 (FMR1) gene associated
with a reduced QIDS-SR depression self-rating, which have been dis-
cussed in more detail elsewhere [36], but a somewhat different
statistical model is presented here to provide perspective and com-
parison. Additional Bonferroni-signiﬁcant results were as follows.
Rs6888451 in peroxisome proliferator-activated receptor gamma,
coactivator 1 beta (PPARGC1B) was associated with the number of
obstructive apneas, with the obstructive apnea index, with the per-
centage of the sleep time that oxygen saturation was below 80%,
and with the ODI3, which are all related phenotypes representing
slightly different perspectives on obstructive sleep-disordered breath-
ing. Rs3923809 of BTBD9 was inversely associated with the log
transform of the leg movement index, loglmindexp1. Rs10766071
of aryl hydrocarbon receptor nuclear translocator-like (ARNTL) was
associated with reduced polysomnographic total sleep time, tstpsg,
in the recordings with tib >300 min. Rs11552085 in casein kinase
1 delta (CSNK1D) was associated with polysomnographic sleep
latency, sleeplatpsg. The distribution of central apneas was highly
skewed, with most patients scored as having none, so the linear re-
gression of central apneas with retinoic acid receptor-related orphan
receptor A (RORA) rs8025324 shown as Bonferroni signiﬁcant was
not evidence of reliable association (a Kruskal–Wallis nonparamet-
ric comparison of the three genotypes showed no signiﬁcant
association with central apneas). Rs11071547 in RORA was associ-
ated with questionnaire-reported sleep latency. Finally, rs4964515
in cryptochrome 1 (CRY1) was associated with the questionnaire-
reported weekday time of falling asleep, fallasleep. The main results
are presented in more detail in Supplement S1 along with addi-
tional results not achieving Bonferroni criteria of signiﬁcance.
The reliability of 13 Bonferroni-signiﬁcant associations among
regressions with a total of 38 phenotypes is diﬃcult to appraise,
considering that various SNPs were genetically linked and various
phenotypes were intercorrelated. An overall perspective was offered
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by q false-discovery statistics, which estimate the chances of a false-
positive discovery among multiple comparisons [43]. The overall q
statistics were computed by compiling the P values for all of the SNP
regressions for all phenotypes in combination, a total of 23,294 P es-
timates. The false-discovery estimates were as follows: for rs4964515
in CRY1, P = 1.99E-07 and q = 0.0045. For P values of 8.28E-06 to 1.09E-
05, the risk of false discovery was estimated as q = 0.062. For P values
of 2.62E-05 to 7.82E-05, qwas estimated as 0.107–0.125. In otherwords,
the Bonferroni-signiﬁcant P values ranging from 8.28E-06 to 7.82E-05
had chances of roughly 6–13% of representing false discoveries. For P
values of 0.000107–0.000895, q was estimated as 0.161–0.495. These
estimates indicate that P values exceeding 0.000934 were >50% likely
to be false discoveries, for example, a nominal P >0.0208was about 90%
likely to be a false discovery. A graphic perspective is presented by Fig. 1,
a quantile–quantile plot of the same 23,294 P values, which shows the
observed P values below the Bonferroni criteria to be rather close to
the randomexpectation. The Bonferroni-signiﬁcant valueswere some-
what above expectation, but only the observed P value near 10−7 was
impressively above the randomexpectation illustrated in theQ–Q plot.
We examined the genotypes from the 86 subjects of non-
European ancestry to investigate if any of the Bonferroni criteria
associations shown in Table 1 were replicated among the non-
Europeans, but none of the 13 speciﬁc associations met even a
nominal P < 0.05 criterion for replication signiﬁcance.
4. Discussion
A genetic survey of a heterogeneous group of sleep disorders
patients yielded a substantial collection of ﬁndings, largely novel and
surprising.Recruitingunselectedpatientsundergoingpolysomnograms
for genetic studies appears to be a fruitful strategy. From the false-
discoverystatistical estimates,wewouldanticipate that theBonferroni-
signiﬁcant SNPs inTable1 include some falsepositives, butmost of the
Bonferroni-signiﬁcant resultsmightbe truediscoveries.Of course,most
SNPsmerelynominally signiﬁcant in realitywere likely tobe “falsedis-
coveries.”EvenBonferroni-signiﬁcantassociationsshouldbeconsidered
tentative until replicated by independent research groups, particularly
since none of the associations could be replicated in our small sample
of non-European ancestry.
Perhaps themost important resultwas the association of PPARGC1B
rs6888451 with several measures reﬂecting obstructive sleep apnea.
Of the 601 patients (83%) who had <10 obstructive apneas per hour,
only 19% had one or two copies of the minor allele of rs6888451, but
of the 17 (2%) who had >50 obstructive apneas per hour, 65% had one
minor allele. As shown in Fig. 2, those with at least oneminor G allele
averaged almost twice asmany total obstructive apneas as the homo-
zygotes for the common allele. Likewise, those with one minor allele
had almost twice the obstructive apneas per hour, 61% more oxygen
desaturations per hour, and six times asmany central apneas (NS). The
less signiﬁcant associations of rs6888451 with the number of central
apneas and theAHI (the apnea–hypopnea index includes central apneas)
might suggest that an obstructing apnea mechanism was mainly
Table 1
Linear regression P values for key phenotypes.
loglm insomnia tstpsg sleeplat sleepeff centraln obstrn obstrai under80 ahitst odi apnea qids subj fall
indexp1 psg index score latency asleep
GENE SNP Yellow highlights regressions P<0.05 Pink highlights Bonferroni-significant associations:
PPARGC1B rs6888451 0.9088 0.4794 0.3468 0.9707 0.4700 0.0295↑ 1.1E-5↑ 6.7E-5↑ 1.0E-5↑ 0.0005↑ 8.9E-6↑ 0.0149↑ 0.4027 0.5810 0.7019
BTBD9 rs3923809 2.6E-5↓ 0.9582 0.0363↑ 0.1005 0.0015↑ 0.2978 0.6162 0.4390 0.8652 0.9165 0.7514 0.4408 0.7474 0.1446 0.8208
ARNTL rs10766071 0.4608 0.4129 5.3E-5↓ 0.0105↑ 0.0001↓ 0.6207 0.2841 0.8111 0.6495 0.8050 0.2823 0.6675 0.9508 0.0431↑ 0.2160
CRY1 rs4964515 0.0115↑ 0.6784 0.9528 0.6559 0.6740 2.0E-7↑
RORA rs11071547 0.0321↑ 0.8747 0.3310 0.8660 0.3401 0.9158 0.6053 0.6901 0.8465 0.9544 0.6749 0.8752 0.4026 5.5E-5↑ 0.2182
RORA rs8025324 0.7721 0.9585 0.2979 0.1367 0.5310 7.8E-5↑ 0.7174 0.7931 0.0956 0.1942 0.1039 0.2672 0.2670 0.4574 0.1391
CSNK1D rs11552085 0.0322↑ 0.1637 2.9E-5↑ 0.5303 0.8152 0.0087↑
FMR1 rs28900 0.3302 3.3E-5↓ 0.5791
FMR1 rs25714 0.2312 6.2E-5↓ 0.6240
FMR1 rs25702 0.2329 6.1E-5↓ 0.6232
Beta:  B= -0.18 B= -55.96 B=46.98 B=8.86 B=16.48 B=5.49 B= 1.26 B=7.35 B= -0.15 B=5.77B= 0.097
Bonferroni P: <0.02 <0.05 <0.02 <0.05 <0.01 <0.05 <0.05 <0.006 <0.05 <0.05 <0.0002
PHENOTYPES:
Note: For deﬁnitions of the phenotypes, details of the regression models, regression results for additional phenotypes, and more detailed regression results, see
Supplement 1. Beta (B) is the unstandardized regression coeﬃcient (the same for all three Bonferroni-signiﬁcant linked FMR1 SNPs). Blanks represent SNP associations not
estimated by the models due to the low minor allele frequencies of rs4964515 and rs11552085 among Europeans and the impact of gender covariates on PLINK chromo-
some X analyses. Positive beta (B) values, ﬂagged for nominal P < 0.05 associations by ↑ symbols, indicate that the minor allele was associated with increased phenotype
quantity. Negative B values, ﬂagged by ↓ symbols, indicate a minor allele associated with decreased phenotype quantity. The Bonferroni P is the probability of the associ-
ation, conservatively adjusted for the number of SNPs tested within each regression.
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Fig. 1. Quantile–quantile plot of P values. The ranked P values of SNP associationswith
sleep phenotypes are plotted with x symbols for 23,294 P values. The values above the
Bonferroni-corrected criteria for P < 0.05 (thick dashed line)were approximately one log
unit above the randomexpectations (i.e., P values ~0.10 times randomexpectations). Only
the single association for rs4964515 in CRY1with the questionnaire-reportedweekday
time of falling asleep was substantially above the random trend (P = 1.99E10-7).
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involved, such as airway anatomic compromise or collapsibility or
inadequate airway dilator responses [44,45], or it might simply reﬂect
that most patients had no central apneas scored. It was conﬁrmatory
that, besides the direct indices of obstructive apnea, the ODI3 (≥3%
oxygen desaturations per hour) and the under 80% desaturation index
(phenotype indices reﬂecting sleep-disordered oxygen desaturations)
were also strongly associatedwith rs6888451. That the apnea scorewas
associated with only weak nominal signiﬁcance might suggest either
a closer association of rs6888451with objectivemeasures of apnea than
with clinician diagnostic formulations, or it might suggest that the
logarithmic transform of ODI3 and AHI weaken the correlation by
de-emphasizing themost severe cases of respiratory disturbanceswith
which the rs6888451 minor allele was predominantly associated.
We had no a priori reason to expect that PPARGC1B would inﬂu-
ence sleep apnea. The gene had been included in the SNPpanel because
of previous indications relating PPARGC1B to depression [36,46] and
because PPARGC1B is a transcription factor binding at RRE sites of cir-
cadian genes, for example, weakly associatedwith delayed sleep phase
and eveningness in a different sample [37]. An article reporting
PPARGC1B rs7732671 associated (P = 0.004)with reduced obesity [47]
was citedbyNCBIOMIM,butwecouldnotﬁnd replicationof anyobesity
association with PPARGC1B in more recent very large genome-wide
association studies (GWASs) [48]. We did not observe an association
of rs6888451 either with rs7732671 or with weight and body mass
index (BMI), and using BMI as a covariate in the regressions had no sub-
stantial effect on the association of rs6888451 with apnea variables.
However, rs32574, an SNP6643nucleotides 3′ of rs7732671,wouldhave
met the Bonferroni criteria for association with body weight, had the
P valuenotbeen corrected for genomic inﬂation.According to theScripps
GenomeAdviser [49], rs6888451 is part of a SMAD3 transcription factor
binding site. TheUniversity ofWashington “Seattle SNPs”GenomeVari-
ation Server 138 and the SNAP Annotation and Proxy Search website
[50] suggested nine additional common intronic SNPs with R2 = 1.0
linkage to rs6888451 and at least 13 other intronic SNPs with R2 >0.5,
at least one of which is part of muscle initiator sequence 19 [49]. If the
association of rs6888451with sleep-disordered breathing can be rep-
licated, itmight thus require considerablemolecular biology to identify
which among the linked variants might be causal. Among the partici-
pants of non-European ancestry, although there were no signiﬁcant
associationswith PPARGC1B, the four homozygotes for the rs6888451
minor allele tended to have themost respiratory disturbance, with the
heterozygote intermediate.
Another important group of ﬁndingswas SNPs associatedwith short
and disturbed sleep. The minor allele of ARNTL rs10766071 was
signiﬁcantly associated with shorter polysomnographic total sleep
(Bonferroni P < 0.05) and nominally associated with increased sleep
latency (both questionnaire and PSG), with delayed sleep-phase clas-
siﬁcation, with poor sleep eﬃciency, andwith reduced REM sleep. See
Fig. 3. The Scripps Genome Adviser [49] identiﬁed no speciﬁc func-
tional role for this SNP, but it is perfectly linked (R2 = 1.0)with a nearby
intronic linkage block, andwith onepromoter SNP, rs7126225. In a large
GWAS [14], rs10766071was signiﬁcantly associatedwithquestionnaire-
reportedhome total sleep time (P =0.043), but a number of otherARNTL
SNPs including rs7126225 (P = 0.012) were more signiﬁcantly associ-
ated, and the strongest association with home total sleep was with a
potassiumchannel on chromosome12,whichhappens to be rather near
a homologue, ARNTL2. Our study might be thought a partial replica-
tion of the GWAS ARNTL results [14], except that our own similar
questionnaire-reported home sleep time data were not signiﬁcantly
associated with ARNTL SNPs. When our polysomnographic data were
limited to tib >300 min., tib was also nominally associated with
rs10766071 (P = 0.0003), so it is uncertain whether there might be a
mutual interaction of tib and tstpsg in this data set limited to tib >300.
Possibly delayed sleep onset, as indicated by long sleep latencies and
DSPS symptoms, caused both curtailed tib and tstpsg in interactionwith
laboratory scheduling of polysomnography. Interestingly, some RORA
SNPs were nominally associated with questionnaire sleep duration in
the GWAS [14] as were rs8025324, rs9806633, and rs12907550 in our
study, but the SNPs highlighted in the GWAS supplement were not
among thosewe assayed, and the RORA gene is so large that nominal-
ly signiﬁcant falsediscoveries are tobeexpected. Theassociationof RORA
rs11071547 we observed with the subjective sleep latency met the
Bonferroni criteria in our study, with nominally signiﬁcant associa-
tionswith legmovement indices and a restless legs complaint, hinting
that rs11071547maymediate prolonged sleep latency partly through
restless legs and periodic limb movements. Nominally signiﬁcant as-
sociations of differentRORA SNPswith sleepdurationwere also reported
by Utge et al. [51] along with Bonferroni-signiﬁcant associations of
subjective sleep duration (among females only) with an SNP in GRIA3.
Suggestive association of SNPs with questionnaire sleep duration was
also reported by Ollila et al. [52]. Since short and long sleep are asso-
ciatedwith excessmortality, it is possible that someof these SNPsmight
be found to bemortality predictors. If so,more complex analyses based
on Mendelian randomization of the SNP variables considered as in-
strumental variables inﬂuencing sleepdurationmight allowexploration
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ofwhether sleep duration variation in itselfmediates themortalitywith
which it is associated.
As previously reported [53],BTBD9 rs3923809was associatedwith
thelegmovement indiceswithBonferronisigniﬁcance.Thelesscommon
allele isassociatedwith fewer legmovements (Fig.4).BTBD9 rs3923809
wasalsonominally associatedwithpolysomnographic total sleep time,
sleep eﬃciency, and REM latency, all of which associations might be
mediated by periodic limbmovements causing sleep disturbance. Our
ﬁndingspartially replicate theprevious reports of Stefanssonet al. [53]
andWinkelmann, et al. [54]. However, we did not replicate any asso-
ciation of rs3923809 with restless legs, nor could we replicate an
associationofanyofﬁveMAP2K5SNPswithrestless legs[54],anoutcome
rather similar to that in the Wisconsin cohort [55]. One limitation of
our methodwas that we did not isolate an RLS subsample focused on
thosewith familialRLS [56].Butour strategywasdirected towardsSNPs
that would impact RLS susceptibility in a sleep clinic sample in which
familialitywasnot a criterion.AnassociationofMEIS1 rs6710341with
restless legs [57]was conﬁrmedby the replication criterionof P < 0.05,
but the association of rs2300478 [13] was not replicated in the ques-
tionnairedata. Inasupplementary logisticregressionbasedonphysician-
recorded research diagnoses of restless legs syndrome (not shown), of
the nine SNPs of BTBD9,MEIS1, andMAP2K examined for replication,
only MEIS1 rs2300478 reached nominal signiﬁcance (P < 0.05).
Two other SNPs related to phenotypes of disturbed sleep were
CSNK1D rs11552085 and CRY1 rs4964515. Both were nominally
associated with reduced subjectively reported total sleep time, with
subjective insomnia, and with later reported clock times to fall asleep
bothonweekdays andonweekends. InCSNK1D, heterozygotes (N = 8)
with the minor allele of rs11552085 were associated with 3.37 times
the polysomnographic sleep latency (Bonferroni P < 0.02), but the ﬁve
participants of non-European ancestry with one or two minor alleles
didnothave longer sleep latencies. ForCRY1 rs4964515, theBonferroni
P = 1.99E-07 for reported time falling asleep was the smallest P value
obtained in all the analyses, and asmentioned above, thiswas the only
associationwith a false-discoveryprobability of q = 0.0045, suggesting
statistical reliability. As shown in Fig. 5, this highly signiﬁcant contrast
was derived largely from one outlying participant’s very late reported
timeof fallingasleeponweekdays(amongonly11withtheminorallele),
as the reported time of falling asleep onweekends was several orders
ofmagnitude less signiﬁcant, and thepolysomnographic sleep latency
was not associated with CRY1 SNPs at all. The Mann–Whitney rank-
order contrast of the two groupswas signiﬁcant only at the P = 0.0001
level.Moreover, our sampleof non-Europeanancestryhad included23
participants with an rs4964515minor allele, and theminor allele had
nosigniﬁcantassociationwithanyphenotype.No indicationof asimilar
association of rs4964515with delayed falling asleepwas found in our
companion sample of DSPS cases and controls [37]. For these reasons,
despite the very small estimated q value, we must be quite skeptical
that this rs4964515associationwasa truepositiveuntil replicated, and
the same is true of the rs11552085 ﬁndings. It is notable that neither
rs11552085norrs4964515showedevidenceofDSPSontheBALMscale,
so the meaning of a delayed sleep onset would be uncertain.
The signiﬁcant protective association of FMR1 SNPswith the QIDS-
SR depression scale has beenmore extensively discussed in a previous
paper [36], but here we note the interesting nominally signiﬁcant
protective associations of the same SNPs with excessive sleepiness as
indicated by decreased ESS. From a genetic viewpoint, it might appear
that depression might be the main mechanism of reported daytime
sleepiness in this Sleep Center sample. Genotypes aside, we have
similarly found the ESS to be more closely correlated with the QIDS-
SR than with any apnea, RLS, or leg movement index (data not
presented), a ﬁnding resembling previous reports of Bardwell et al. [58].
Similarly, the insomnia scale (which was derived from the ﬁrst three
items of the QIDS-SR) was also associated with the three FMR1 SNPs.
To highlight the variability of clinical samples and the risks of false
discovery, it is worth reviewing some pertinent negative results of this
study. For example, Gottlieb et al. conﬁrmed the heritability of sleep
disorder phenotypes in Framingham data; however, using FBAT sta-
tistics,which are not subject to genomic inﬂation on FraminghamGWAS
data, they located no SNP associated with a sleep phenotype with
Bonferroni signiﬁcance after correcting formultiple-testing inﬂation [31].
The one SNP association meeting Bonferroni signiﬁcance with
population-based statistics, rs1823068, did not replicate at all in our
data (see Supplement S1.). Some tentative associations (inconsistent
in two races and of questionable statistical reliability) have been re-
ported for obstructive sleep apnea [59,60], but a recent review found
apnea-association reports that could be meta-analyzed only for an-
giotensin I converting enzyme (ACE), apolipoprotein E (APOE4) [33,61],
and tumor necrosis factor alpha (TNFalpha) [62–65], and only TNFalpha
was supportedbymeta-analysis (possiblymediatedby associationswith
heart failure).We could not conﬁrm associations of APOE or TNFalpha
in our data. The dominant polymorphism in period circadian clock 2
(PER2) associated with advanced sleep phase disorder (ASPD) seems
quite rare [66,67], and we did not ﬁnd it. A much-studied polymor-
phism reported to be associated with DSPD, the C3111T SNP in
CLOCK (rs1801260) [68], was not a signiﬁcant correlate of DSPD or
morningness–eveningness in the sleep center data [37].Wedid conﬁrm
some previous associations of periodic leg movements and RLS with
rs3923809 and rs6710341 while failing to conﬁrm other reported
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associations. In one report, a larger number of SNPs from three genes
appeared to explain more than half of the total RLS risk [57]. In an
expansionof that studyexamining the associationof RLSwith six genetic
risk loci, the explained genetic variance was estimated at 6.8%
[13,69].
5. Conclusions
In summary, this report introduces valuable clues to sleep disor-
ders, which might be pursued by greatly expanding genetic research
in patients studied in the sleep center clinical setting. Previous expe-
rience emphasizes the importance of independent replications of our
results before their value can be conﬁrmed in clinical application.
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